Hereditary Angioedema Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Hereditary Angioedema Therapeutics Market Report is segmented By Drug class (Kallikrein Inhibitor, C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Others), By Treatment Type (On-demand, Prophylaxis), By Route of Administration (Intravenous, Subcutaneous, Oral), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Hereditary Angioedema Therapeutics Market Size

The Global Hereditary Angioedema Therapeutics Market reached USD 2.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 5.4 billion by 2031. The global hereditary angioedema therapeutics market is expected to exhibit a CAGR of 8.6% during the forecast period (2024-2031). The global hereditary angioedema therapeutics market has grown significantly in recent years and is projected to continue on its upward trend.

The market is currently going through a period of significant change that is being fueled by a number of trends, such as the growing adoption of prophylactic therapies, focus on patient-centric approaches and the introduction of novel therapies.

Furthermore, the increasing prevalence of hereditary angioedema, advancements in treatment options, increasing healthcare expenditure, and augmenting support from non-profit organizations towards intensive research are driving up the size of the hereditary angioedema therapeutics market. Due to continuous research and developments through the introduction of novel drugs, formulations, and treatments, the market is seeing an increase in demand from North American regions. Significant competitors like BioCryst Pharmaceuticals, Inc, CSL Behring LLC, Takeda Pharmaceutical Company, and others are actively operating in the market.

Hereditary Angioedema Therapeutics Market Scope

For more insights - Download Sample

Hereditary Angioedema Therapeutics Market Dynamics

The Increasing Prevalence of Hereditary Angioedema to Drive the Growth of the Hereditary Angioedema Therapeutics Market

The increasing prevalence of hereditary angioedema is a major driver of the need for better treatments. This refers to an increase in the number of people diagnosed with hereditary angioedema, a rare genetic condition that causes periodic bouts of swelling. Several factors are contributing to the increase in prevalence. For example, there has been more awareness and improved diagnostic tools, leading to more accurate identification and diagnosis of cases of hereditary angioedema. 

For instance. research released in May 2022 by the National Center for Biotechnology Information, estimated prevalence of hereditary angioedema to be 1 in 50,000 people worldwide. Furthermore, according to the National Organisation for Rare Disorders (NORD), there is a 50% chance of passing the abnormal gene from an affected parent to their offspring during each pregnancy, regardless of the child's gender. Thus, owing to the above reason the market is expected to drive over the forecast period.

The Increasing Support from Non-profit organizations will Drive the Demand for Hereditary Angioedema Therapeutics Market

The hereditary angioedema therapeutics market is expected to grow due to greater support from non-profit organizations for extensive research. These organizations play an important role in expanding scientific understanding, enhancing diagnosis and therapy choices, and assisting in the overall management of hereditary angioedema.

For instance, the U.S. Hereditary Angioedema Association, Inc. is a non-profit organization committed to assisting people affected by CI inhibitor deficiency. Their objective entails boosting disease awareness and providing thorough, conveniently available information to individuals and healthcare professionals. The organization serves as a resource for patients and an advocate for research focused on creating effective medications and finding a cure for the ailment. This drives the market growth over the forecast period.

High Cost of Treatment will Hamper the Growth of the Market. 

The high treatment costs make hereditary angioedema treatments less accessible, especially in underdeveloped countries with limited healthcare budgets. Patients in these areas may struggle to finance the necessary therapies, resulting in hurdles to adequate care. 

For instance, a single supply of Ruconest intravenous powder for injection costs around $7,665.00. Furthermore, Firazyr, Berinert, and Kalbitor had total expenses of $7.97 Billion, $7.90 Billion, and $11.33 Billion, respectively. These expenses equate to a per-member-per-month (PMPM) cost of $0.66 for Firazyr and Berinert and $0.94 for Kalbitor. Considering these factors, the high treatment costs limit access to hereditary angioedema therapeutics, thereby affecting market growth.

Hereditary Angioedema Therapeutics Market Segment Analysis

The global hereditary angioedema therapeutics market is segmented based on drug class, treatment type, route of administration, and region.

Owing to the Effectiveness, the C1 Esterase Inhibitors Segment Accounted for Approximately 41.4% of the Hereditary Angioedema Therapeutics Market Share

C1 Esterase Inhibitors are expected to dominate the market because they have shown to be a popular and well-liked therapeutic choice for hereditary angioedema. They have an extensive clinical usage history and a well-established safety and effectiveness profile. The use of recombinant technology and improvements in manufacturing procedures have increased the accessibility and availability of C1 Esterase Inhibitors. As a result, people in need can now more easily get these medicines. 

C1 Esterase Inhibitors are versatile in managing both acute attacks and as a preventative medication, allowing patients with hereditary angioedema to effectively address their different demands. C1 Esterase Inhibitor (Human) is an example of a C1 Esterase Inhibitor, which is a pure endogenous complement component-1 esterase inhibitor produced from human plasma. This endogenous C1 Esterase Inhibitor's major role is to modulate the activation of the complement and contact system pathways.

For instance, in December 2022, Takeda Biopharmaceuticals India (previously known as Baxalta Bioscience India) launched CINRYZE, a novel injectable prescription drug developed to treat individuals with hereditary angioedema (HAE). This introduction highlights the market's continued development and availability of C1 Esterase Inhibitors. Thus owing to the above factors, the segment will continue to dominate the market over the forecast period.

Source: DataM Intelligence Analysis (2023)

Hereditary Angioedema Therapeutics Market Geographical Share

North America Accounted for Approximately 39.7% of the Market Share in 2022, Owing to Technological Advancements and Better Government Initiatives

North America is expected to dominate the hereditary angioedema therapeutics market due to several key factors. The region has an established healthcare system and a high level of awareness regarding hereditary angioedema. There are frequent product introductions and clinical trials in North America, as well as a large number of diagnosed patients. The existence of big pharmaceutical corporations, as well as ongoing research initiatives, contributes to North America's market dominance.

For instance, in February 2022, Takeda Pharmaceuticals presented their study findings on the treatment of Hereditary Angioedema (HAE) with TAKHZYRO (lanadelumab) at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 78th Annual Meeting. The presentation included four abstracts that provided interim real-world data from the North American Phase 4 EMPOWER project. 

The study looked at the efficacy of TAKHZYRO in people with HAE Type I or II. The presentation also included results from a post-hoc analysis of the HELP Open Label Extension research, which looked at the long-term safety and efficacy of TAKHZYRO in HAE patients aged 12 and above. Overall, these factors establish North America as a leading region in the field of hereditary angioedema therapeutics.

Source: DataM Intelligence Analysis (2023)

Hereditary Angioedema Therapeutics Market Companies 

The major global players in the hereditary angioedema therapeutics market include BioCryst Pharmaceuticals, Inc, CSL Behring LLC, Takeda Pharmaceutical Company, Pharming Healthcare, Inc, Sanofi, Attune Pharmaceuticals, Inc, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, and Advanced Technology & Industrial Co., Ltd, among others. 

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict has the potential to have an influence on the global market for hereditary angioedema treatments. Possible consequences include supply chain disruptions, limited access to healthcare and treatment in affected areas, economic ramifications on healthcare budgets, and a potential delay in research and development efforts. It is critical to keep a close watch on the situation in order to comprehend the market's specific consequences.

Key Developments

• On February 9, 2023, Astria Therapeutics began the Phase Ib/II ALPHA-STAR clinical trial of STAR-0215 to treat patients with hereditary angioedema (HAE). The open-label, global Phase Ib/II proof-of-concept trial will evaluate STAR-0215 as a potential long-acting therapy to prevent HAE attacks.
• On March 3, 2023, the FDA approved Intellia Therapeutics' investigational new drug (IND) application for NTLA-2002, an in vivo CRISPR-based investigational therapeutic, allowing the company to begin a trial to treat hereditary angioedema (HAE).
• On January 27, 2023, BioCryst Pharmaceuticals enrolled the first patient in the pivotal APeX-P study of Orladeyo (berotralstat) in pediatric hereditary angioedema (HAE). The open-label APeX-P trial was designed to evaluate Orladeyo's safety and pharmacokinetics (PK) in pediatric HAE patients aged two to less than 12 years old.

Why Purchase the Report?

• To visualize the global hereditary angioedema therapeutics market segmentation based on drug class, treatment type, route of administration, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of hereditary angioedema therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global hereditary angioedema therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies